person · Reporting owner
Williams Paul Christopher
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | CHIEF OPERATING OFFICER | August 19, 2024 | August 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 19, 2024 · Filed August 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,473 |
Ending reported balance
After 2024-08-19 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-08-19 · Exercise / conversion · Acquired 1,006 · Balance 10,908 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2024-08-19 · Tax withholding · Disposed 392 · Balance 10,516 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2024-08-19 · Exercise / conversion · Acquired 920 · Balance 11,436 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2024-08-19 · Tax withholding · Disposed 359 · Balance 11,077 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2024-08-19 · Exercise / conversion · Acquired 8,840 · Balance 19,917 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2024-08-19 · Tax withholding · Disposed 3,444 · Balance 16,473 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,063 |
Reported balance
After 2024-08-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-08-19 · Exercise / conversion · Disposed 1,006 · Balance 9,063 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,513 |
Reported balance
After 2024-08-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-08-19 · Exercise / conversion · Disposed 920 · Balance 9,513 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 126,709 |
Reported balance
After 2024-08-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-08-19 · Exercise / conversion · Disposed 8,840 · Balance 126,709 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18.
F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.
F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 8,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · derivative · entry 9 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,709 Underlying: Common Stock · 8,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 920 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · derivative · entry 8 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,513 Underlying: Common Stock · 920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · derivative · entry 7 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,063 Underlying: Common Stock · 1,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 3,444 | $5.53 | $19,045.32 |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · nonDerivative · entry 6 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,473 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 8,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · nonDerivative · entry 5 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 359 | $5.53 | $1,985.27 |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · nonDerivative · entry 4 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,077 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · nonDerivative · entry 3 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 392 | $5.53 | $2,167.76 |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · nonDerivative · entry 2 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,516 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021856 · form4-08212024_100816.xml · nonDerivative · entry 1 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · derivative · entry 9 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,549 Underlying: Common Stock · 5,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 613 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · derivative · entry 8 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,433 Underlying: Common Stock · 613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · derivative · entry 7 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,069 Underlying: Common Stock · 1,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,296 | $5.96 | $13,684.16 |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · nonDerivative · entry 6 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,902 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · nonDerivative · entry 5 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 239 | $5.96 | $1,424.44 |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · nonDerivative · entry 4 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,305 Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · nonDerivative · entry 3 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 392 | $5.96 | $2,336.32 |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · nonDerivative · entry 2 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,931 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014147 · form4-05222024_100534.xml · nonDerivative · entry 1 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F1 · balance_after: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007870 · form4-03132024_100335.xml · derivative · entry 3 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,046 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 478 | $7.22 | $3,451.16 |
DisclosureSEC source: 0001415889-24-007870 · form4-03132024_100335.xml · nonDerivative · entry 2 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,317 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 11, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-007870 · form4-03132024_100335.xml · nonDerivative · entry 1 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 141,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007439 · form4-03082024_110311.xml · derivative · entry 2 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,442 Underlying: Common Stock · 141,442 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 210,526 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-24-007439 · form4-03082024_110311.xml · derivative · entry 1 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,526 Underlying: Common Stock · 210,526 shares Expires 2034-03-06 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 6, 2024 and each month thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004898 · form4-02222024_100248.xml · derivative · entry 3 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,075 Underlying: Common Stock · 1,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 392 | $8.38 | $3,284.96 |
DisclosureSEC source: 0001415889-24-004898 · form4-02222024_100248.xml · nonDerivative · entry 2 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,568 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004898 · form4-02222024_100248.xml · nonDerivative · entry 1 Williams Paul Christopher · CIK 0001951234 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056351 · doc4.xml · derivative · entry 6 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,273 Underlying: Common Stock · 920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056351 · doc4.xml · derivative · entry 5 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,081 Underlying: Common Stock · 4,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 359 | $5.98 | $2,146.82 |
DisclosureSEC source: 0001209191-23-056351 · doc4.xml · nonDerivative · entry 4 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,954 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056351 · doc4.xml · nonDerivative · entry 3 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,569 | $5.98 | $9,382.62 |
DisclosureSEC source: 0001209191-23-056351 · doc4.xml · nonDerivative · entry 2 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,393 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:56 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056351 · doc4.xml · nonDerivative · entry 1 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:16 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046829 · doc4.xml · derivative · entry 3 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,193 Underlying: 08/18/2023 · 920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:16 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 359 | $8.46 | $3,037.14 |
DisclosureSEC source: 0001209191-23-046829 · doc4.xml · nonDerivative · entry 2 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 935 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:16 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046829 · doc4.xml · nonDerivative · entry 1 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 613 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031265 · doc4.xml · derivative · entry 3 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,113 Underlying: Common Stock · 613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 239 | $6.69 | $1,598.91 |
DisclosureSEC source: 0001209191-23-031265 · doc4.xml · nonDerivative · entry 2 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031265 · doc4.xml · nonDerivative · entry 1 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 00:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 14,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016981 · doc4.xml · derivative · entry 2 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,726 Underlying: Common Stock · 14,726 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 00:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock option (right to buy) · Derivative | 22,257 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001209191-23-016981 · doc4.xml · derivative · entry 1 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,257 Underlying: Common Stock · 22,257 shares Expires 2033-03-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:48 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 16,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055368 · doc4.xml · derivative · entry 2 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,108 Underlying: Common Stock · 16,108 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and 3/48 of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on February 18, May 18, August 18 and November 18. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:48 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock option (right to buy) · Derivative | 24,601 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-22-055368 · doc4.xml · derivative · entry 1 Williams Paul Christopher · CIK 0001951234 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,601 Underlying: Common Stock · 24,601 shares Expires 2032-10-31 F1 · derivative.exercise_date: The shares subject to the option shall vest as follows: 25% of the shares shall vest on October 31, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.